These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 4176410)

  • 21. [Blood and fractionation of blood].
    Soeterboek AM
    Pharm Weekbl; 1969 Dec; 104(50):1578-601. PubMed ID: 4188429
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hereditary systems of human immunoglobulins and legal medicine].
    Ropartz C; Rivat L
    Rev Fr Transfus; 1969; 12(1):Suppl:155-62. PubMed ID: 4193517
    [No Abstract]   [Full Text] [Related]  

  • 23. The Gm and Inv allotypes of some Ashkenazic Jews living in Northern U.S.A.
    Steinberg AG
    Am J Phys Anthropol; 1973 Nov; 39(3):409-11. PubMed ID: 4753138
    [No Abstract]   [Full Text] [Related]  

  • 24. [Serum factors Gm and Inv in the population of Brno].
    Hill Z; Krejcová O
    Vnitr Lek; 1968 Feb; 14(2):174-6. PubMed ID: 4170209
    [No Abstract]   [Full Text] [Related]  

  • 25. Distribution of Gc types in Northern Italy.
    Cleve H; Vierucci A
    Acta Genet Stat Med; 1965; 15(3):243-7. PubMed ID: 5899184
    [No Abstract]   [Full Text] [Related]  

  • 26. [Studies on immunoglobulin hereditary traits (Gm-and InV groups) in subhuman primates].
    Schmitt J; Krüpe M; Deicher H
    Humangenetik; 1965; 1(6):571-3. PubMed ID: 5868433
    [No Abstract]   [Full Text] [Related]  

  • 27. [Factor P: frequency in the population of Pescara].
    Pontano O; Di Sapia L; Madeo D
    Ann Sclavo; 1973; 15(2):200-6. PubMed ID: 4775028
    [No Abstract]   [Full Text] [Related]  

  • 28. [THE HUMAN BLOOD GROUPS. STUDY OF THE FREQUENCY OF THE GM AND INV GROUPS IN A SAMPLE OF THE POPULATION IN THE REGION OF LYONS].
    BETUEL H; REVOL L; ROPARTZ C; ROUSSEAU PY; RIVAT L
    J Med Lyon; 1963 Jun; 44():1053-68. PubMed ID: 14078027
    [No Abstract]   [Full Text] [Related]  

  • 29. A new inheritable property of human sera: the InV factor.
    ROPARTZ C; LENOIR J; RIVAT L
    Nature; 1961 Feb; 189():586. PubMed ID: 13743200
    [No Abstract]   [Full Text] [Related]  

  • 30. [INCIDENCE OF M,N,S, S AND P FACTORS IN A SAMPLE OF THE ROMAN POPULATION].
    DEBARTOLO M
    Acta Genet Med Gemellol (Roma); 1964 Apr; 13():173-81. PubMed ID: 14169793
    [No Abstract]   [Full Text] [Related]  

  • 31. ["Gc" blood groups in the Italian population].
    Spedini G
    Acta Genet Med Gemellol (Roma); 1966 Jan; 15(1):94-108. PubMed ID: 5930174
    [No Abstract]   [Full Text] [Related]  

  • 32. [Temporary modification of the Gm and Inv phenotypes by injection of therapeutic gamma globulins. Medicolegal repercussions].
    Brocteur J; Umani Ronchi G; Beck T
    Zacchia; 1967; 3(3):405-17. PubMed ID: 4181092
    [No Abstract]   [Full Text] [Related]  

  • 33. [On the frequency of the Inv(1) factor in the population living in Latium].
    Carella A
    Zacchia; 1967; 3(1):89-93. PubMed ID: 4176410
    [No Abstract]   [Full Text] [Related]  

  • 34. [The frequency of Inv(1) in the Berlin population].
    Prokop O; Ishiyama I
    Acta Biol Med Ger; 1966; 16(4):459-60. PubMed ID: 4168479
    [No Abstract]   [Full Text] [Related]  

  • 35. [The frequency of gamma globulin serum groups Gm (1, 2, 4, 12) and Inv (1) in normal persons and in patients with carcinoma].
    Wiebecke D; Dickhäuser K; Goecke C
    Bibl Haematol; 1969; 32():64-5. PubMed ID: 4186240
    [No Abstract]   [Full Text] [Related]  

  • 36. The INV(1) factor in the Polish population.
    Schlesinger D
    Arch Immunol Ther Exp (Warsz); 1968; 16(5):742-6. PubMed ID: 4179435
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.